aTyr Pharma Receives Fast Track Designation for Efzofitimod

aTyr Pharma received a Fast Track designation for its investigational candidate efzofitimod in the treatment of patients with systemic sclerosis-associated interstitial lung disease.

Efzofitimod is an immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states through selective modulation of the protein neuropilin-2, the company said.

The investigational treatment also received Fast Track designation from the FDA in August for the treatment of patients with pulmonary sarcoidosis, a form of interstitial lung disease.

The FDA’s Fast Track designation helps facilitate development and expedite the review of drugs to treat serious or life-threatening diseases with unmet need.